-
PROVIDERS
Watch now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
ENROLL NOW
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications.Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
AI-enabled
precision medicine
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Discover our innovative technology
Explore Tempus
LIFE SCIENCES
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery
~65% of all Academic Medical Centers in the US are connected to Tempus
50%+ of oncologists in the US connected to Tempus through sequencing, clinical trial matching, and research-enabled partnerships
95% of the top 20 pharma oncology companies partner with Tempus
200+ biopharma partnerships
~8,000,000 de-identified research records to power scientific discovery to improve patient outcomes
30,000+ patients have been identified for potential enrollment into clinical trials in our network
300+ petabytes of data
Tempus Announces Real World Data Collaboration with BioNTech
Tempus announced a multi-year collaboration with BioNTech that leverages its robust multimodal datasets, analytical support, computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline.
READ PRESS RELEASETempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
Tempus announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower patients and their caregivers to holistically organize, manage, and proactively take control of their own health data.
READ PRESS RELEASETempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
Tempus received 510(k) clearance from the FDA for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF), the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software.”
READ PRESS RELEASEThis is AI-enabled precision medicine
This is the future of healthcare.